Euglycemic DKA (euDKA) as a presentation of COVID‐19

Abstract

Abstract COVID‐19 in the setting of SGLT2 inhibitor use may precipitate euglycemic DKA separate from known acute viral illness and dehydration precipitants. There should be consideration of proactive discontinuation of these medications in these patients.

Keywords

• COVID‐19
• diabetes
• diabetes mellitus
• diabetes type 2
• diabetic ketoacidosis
• euglycemia